CHEK2 variants, breast cancer, and implications for management: a narrative review [0.03%]
CHEK2变异、乳腺癌及对临床诊治的启示：综述
Délio Marques Conde
Délio Marques Conde
Background and objective: Around 6% of female breast cancer (BC) cases are attributed to an inherited predisposition. Of the genes associated with an increased risk of BC, CHEK2 stands out as one of those most commonly id...
Precision diagnosis and treatment of PI3K/AKT/PTEN signaling pathway in HR-positive advanced breast cancer: perspectives from Chinese experts [0.03%]
HR阳性晚期乳腺癌PI3K/AKT/PTEN信号途径精准诊疗中国专家共识意见摘要
Chengcheng Gong,Yue Hu,Yueping Liu et al.
Chengcheng Gong et al.
For hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (BC), the combinations of endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are considered the st...
Predictive potential of hepatocyte growth factor and bone morphogenetic proteins in lymphatic metastasis of breast cancer [0.03%]
肝细胞生长因子和骨形态发生蛋白预测乳腺癌淋巴转移的潜在价值分析
Bin-Bin Cong,Xiao-Shan Cao,Yong-Sheng Wang et al.
Bin-Bin Cong et al.
Background: Lymph node metastasis is an important predictive factor for the prognosis of breast cancer. Bone morphogenetic protein (BMP) and hepatocyte growth factor (HGF), and its receptor MET, are involved in metastasis...
Multimodality evaluation and ultrasound-guided aspiration of a biopsy-proven inspissated clogged milk duct: a case report [0.03%]
经确诊的乳管堵塞病例的多模式评估及超声引导抽吸：病例报告
Kendal L Weger,Nicole P Sandhu,Mohammed Abdelwahed et al.
Kendal L Weger et al.
Background: Despite the benefits of breastfeeding to both infant and mother, many mothers find breastfeeding difficult secondary to many complications such as pain, breast engorgement, mastitis, and clogged milk ducts. Th...
Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2 [0.03%]
中国HER2阳性乳腺癌临床诊断和治疗共识
Jianbin Li,Yueping Liu,Shu Wang et al.
Jianbin Li et al.
Background: Human epidermal growth factor receptor 2 (HER2) is an important driver gene and prognostic indicator of breast cancer and also a key predictor of HER2-targeted therapies. Both the low expression and the positi...
DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer [0.03%]
DESTINY-Breast09带来HER2阳性晚期乳腺癌一线治疗新突破
Jianbing Li,Chunfang Hao,Haibo Wang et al.
Jianbing Li et al.
Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab [0.03%]
针对HR+/HER2低乳腺癌骨转移患者的曲拉珠单抗_deruxtecan疗效：地诺单抗增强疗效
Azzurra Irelli,Leonardo Valerio Patruno,Katia Cannita
Azzurra Irelli
Approximately 60% of human epidermal growth factor receptor 2-negative (HER2-) breast cancers (BCs) are HER2-low [immunohistochemistry (IHC) 1+ or 2+/in situ hybridization (ISH)-]. The proportion of BC patients with hormone receptor-positiv...
Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies [0.03%]
转移性乳腺癌的精准治疗：基于分子改变的治疗方法现状分析
Hafez M A Abdullah,Suma Sri Chennapragada,Rohit Singh et al.
Hafez M A Abdullah et al.
Breast cancer is the most commonly diagnosed cancer in women globally and remains the leading cause of cancer-related death among women. De novo metastatic breast cancer accounts for 5-10% of annual diagnoses, and approximately 30% of women...
Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses [0.03%]
针对不同免疫组化状态的赫赛汀低剂量转移性乳腺癌患者的曲妥珠单抗德鲁昔玛的真实疗效和安全性研究
Song Wu,Jianbin Li,Li Bian et al.
Song Wu et al.
Background: There are limited clinical data to compare the efficacy of trastuzumab deruxtecan (T-DXd) between the immunohistochemistry (IHC) 1+ and 2+ subgroups of human epidermal growth factor receptor 2 (HER2)-low metas...
Key breast cancer highlights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting [0.03%]
2025年美国临床肿瘤学会（ASCO）年会乳腺癌研究亮点
Janhavi Venkataraman,Kefah Mokbel
Janhavi Venkataraman